Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT05742295

Prevention of Cefoperazone-induced Coagulopathy

Conditions: Antibiotic Side Effect

Sex: All

Ages: 18 Years – N/A

Phase: PHASE4

Enrollment: 60

Sponsor: Helwan University

Location: Egypt

Summary

Evaluating the effect of prophylactic doses of vitamin K in preventing the adverse effect of cefoperazone/sulbactam induced coagulopathy in critically ill patients.

Eligibility Criteria

Inclusion Criteria:ICU admitted patients on treatment or prophylactic doses of cefoperazone/sulbactam.Exclusion Criteria:Patients' aged <18 yearsPregnancy or breastfeeding womenActive bleeding or bleeding disorderPatients having an abnormal baseline coagulation profile.Patients administer total parenteral nutrition with regular vitamin k supplements.Refusal to sign the written informed consent.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05742295). StuddyBuddy aggregates publicly available trial information.